|Articles|August 1, 2003

August 2003
Volume 9
Issue 8

Economics of Suboptimal Drug Use: Cost-Savings of Using JNC-Recommended Medications for Management of Uncomplicated Essential Hypertension

Author(s)K. Tom Xu, PhD, Michael Moloney, MD, MPH, Sidney Phillips, PharmD

Download PDF: Economics of Suboptimal Drug Use: Cost-Savings of Using JNC-Recommended Medications for Management of Uncomplicated Essential Hypertension

Articles in this issue

over 22 years ago

Article

What Data Do California HMOs Use to Select Hospitals for Contracting?

over 22 years ago

Article

Patient-Provider Discussions About Conflicts of Interest in Managed Care: Physicians' Perceptions

over 22 years ago

Article

Combination Vaccines

over 22 years ago

Article

Risk Factors for Asthma Hospitalizations in a Managed Care Organization: Development of a Clinical Prediction Rule

over 22 years ago

Article

Analysis of Factors Associated With Increased Prescription Illegibility: Results From the National Ambulatory Medical Care Survey, 1990-1998

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Economics of Suboptimal Drug Use: Cost-Savings of Using JNC-Recommended Medications for Management of Uncomplicated Essential Hypertension

Articles in this issue

Newsletter

Related Content

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD